GLP-1s After Bariatric Surgery: What the Evidence Says in 2026
Weight coming back after gastric sleeve or bypass is common, and adding semaglutide or tirzepatide is now one of the most-studied responses to it. A 2026 randomized trial and a 208,000-patient US cohort finally give real numbers - here is what they found, and what nobody has tested yet.
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.
If you had a gastric sleeve or a gastric bypass and the weight is creeping back, you are not an outlier and you did not fail. Weight recurrence after metabolic and bariatric surgery is common enough that it now has its own research literature, its own treatment algorithms, and as of 2026, its own randomized controlled trial.
This article covers what the evidence actually shows about adding semaglutide (Wegovy, Ozempic) or tirzepatide (Zepbound, Mounjaro) after bariatric surgery: how much weight people lose, which drug performs better, when to start, and how the medication route compares with revision surgery. None of this is medical advice. Where it describes how these drugs are used, it is summarizing the FDA-approved prescribing information and Instructions for Use, not giving instructions; follow your own prescription and your own care team. None of it replaces a conversation with your bariatric team.
Why does weight come back after bariatric surgery?
A 2026 review in Cureus describes weight recurrence after metabolic and bariatric surgery as multifactorial: neurohormonal adaptation, behavioral factors, metabolic compensation, and anatomical changes all contribute [1]. In plain terms, the body defends its weight. Hunger hormones shift back. Portion tolerance expands. The stomach or pouch can stretch. Life happens.
The review is blunt about what this means clinically. Revisional bariatric surgery has historically been the main option, but it is technically more complex and carries higher complication rates than the original operation [1]. That is the gap that incretin drugs stepped into.
One important distinction runs through all of this research. “Insufficient weight loss” means someone never reached a good result after surgery. “Weight recurrence” or “weight regain” means they did, and then some came back. Studies define these differently, which is a big reason the numbers below vary so much.
What did the first randomized trial find?
BARI-STEP is the study to know. Published online in Nature Medicine on May 22, 2026 and printed in the July 2026 issue, it is a double-blind, randomized, placebo-controlled trial of semaglutide 2.4 mg weekly in adults at least one year past gastric bypass or sleeve gastrectomy with a suboptimal clinical response, defined in the protocol as less than 20 percent weight loss from surgery [2].
One thing to know up front, because it is rarely mentioned: BARI-STEP is a UK trial. It recruited at University College London Hospitals and Homerton University Hospitals between November 2022 and April 2025, under NIHR and UCL sponsorship [2]. The drug, the doses and the surgeries are the same ones used in the US, but the care pathway around them is the NHS.
Seventy participants were randomized 1:1 (35 and 35). The average age was 47.3 years, 82.9 percent were women, and mean BMI at enrollment was 41.5. Fifty-five participants (78.6 percent) had had a sleeve gastrectomy and 15 (21.4 percent) a gastric bypass. Everyone got a lifestyle program with a 500 kcal daily energy deficit, for 68 weeks [2].
In the intention-to-treat sample of 63 people (34 on semaglutide, 29 on placebo), mean weight change was -18.0 percent with semaglutide and +0.4 percent with placebo. The adjusted treatment difference was -19.18 percentage points (95 percent confidence interval -23.4 to -14.8, p<0.001) [2].
On safety, the trial reported adverse events consistent with the known semaglutide profile, eight serious adverse events, one suspected unexpected serious adverse reaction, and no treatment-related deaths, with no new safety concerns specific to the post-bariatric population [2].
Two caveats matter. Seventy participants is a small trial. And it enrolled people whose surgery result fell short from the start, not people who did well and later regained. Those may not behave identically.
How much do people lose in real-world practice?
Trials are one thing. Routine care is another, and here the largest dataset is a retrospective cohort published online in EClinicalMedicine on June 23, 2026, drawing on a de-identified electronic health record dataset covering 43,104 academic and private US medical centers between 2018 and 2025 [3].
Of 208,155 people who had metabolic and bariatric surgery, 39,750 received postoperative incretin therapy. Among those who stayed on treatment for a year [3]:
- Tirzepatide: 17.2 percent total weight loss
- Semaglutide: 12.0 percent total weight loss
- Adjusted difference: 5.16 percentage points in favor of tirzepatide (95 percent CI 4.17-6.16, p<0.001), and the effect was dose-dependent
A separate systematic review and meta-analysis in Frontiers in Endocrinology in August 2026, covering 27 papers with 19 in the pooled analysis, reported lower figures: 12-month total weight loss of 9.22 percent with liraglutide and 9.02 percent with semaglutide, with a 4.23 percentage point advantage for tirzepatide over semaglutide at 6 months [4]. The authors flagged substantial heterogeneity and said their findings should be read with caution [4].
Why the spread? Trial participants get structured support, close follow-up and free medication. People in routine care miss doses, hit insurance walls, and stop. Both sets of numbers are true; they just describe different situations.
A small retrospective study in Obesity Research and Clinical Practice adds detail on body composition: in 21 post-bariatric patients without type 2 diabetes, six months of tirzepatide produced 12.0 percent mean total weight loss, with everyone losing at least 5 percent, 76.5 percent losing at least 10 percent, and 23.5 percent losing at least 15 percent [5]. Men and women lost comparable amounts, and differences between bypass and sleeve patients converged by six months [5].
Does it matter when you start?
In the US nationwide cohort, weight loss was greater when incretin therapy started later after surgery. People who started in postoperative months 53 to 79 lost 15.4 percent of total body weight, compared with 13.5 percent for those starting in months 12 to 24 (p<0.001) [3].
Read that carefully. This is an observational association, not a recommendation to wait. People who are still regaining weight five years out are a different group from people who start medication in year two, and the study cannot separate the timing from the reason. Nobody has randomized people to early versus late starts.
The same cohort also looked at heart outcomes. In propensity-matched landmark analyses with inverse probability of censoring weighting, incretin therapy after surgery was not associated with major adverse cardiovascular events (hazard ratio 0.91, 95 percent CI 0.80-1.05, p=0.19) [3]. The authors called for prospective studies to answer whether there is additive cardiovascular protection on top of surgery.
Medication or revision surgery: what does the comparison show?
The largest direct comparison is an academic multicenter retrospective study published in Surgical Endoscopy in July 2025. It looked at 4,901 patients who had insufficient weight loss or weight recurrence after sleeve gastrectomy: 3,004 had conversion to Roux-en-Y gastric bypass, and 1,897 stayed with the sleeve and added weekly injectable semaglutide or tirzepatide [6].
Pre-intervention weight was essentially identical between the groups (242.8 versus 242.3 pounds, p=0.993), though the conversion patients had higher baseline HbA1c [6]. The study tracked weight and HbA1c from three months to three years after the intervention.
It is retrospective. Surgeons and patients chose the path, and the people who chose each one differ in ways statistics cannot fully adjust for. There is no randomized trial here, and the Cureus review’s practical framing is probably the most defensible summary: assess the anatomy first, optimize lifestyle, then consider pharmacotherapy, and reserve revision for genuine anatomical failure [1].
There is also a randomized trial in progress. GRABS (GLP-1 Receptor Agonists Post-Bariatric Surgery) is an open-label proof-of-concept trial of 24 weeks of tirzepatide plus standard of care versus standard of care alone after Roux-en-Y gastric bypass in patients with persistent obesity. Twenty-eight patients completed enrollment, with a median age of 42, a pre-surgery BMI of 48.3 and a BMI at randomization of 36.0 [7]. Results were not published as of September 2026.
Is surgery still better than the drugs for long-term health?
For hard cardiovascular outcomes, the evidence still favors surgery. A network meta-analysis in Endocrinology, Diabetes and Metabolism in September 2026 pooled 43 studies and 932,380 patients [8]:
- Bariatric surgery vs controls: major adverse cardiovascular events hazard ratio 0.66 (95 percent CI 0.60-0.74), heart failure 0.45 (0.38-0.53), myocardial infarction 0.53 (0.45-0.63)
- GLP-1 receptor agonists vs controls: major adverse cardiovascular events 0.85 (0.77-0.94), with non-significant effects on heart failure and myocardial infarction
Heterogeneity was high, between 66 and 93 percent, and the comparisons are mostly indirect [8]. Critically, most of the GLP-1 data in these pools predate the highest-efficacy drugs and doses. People who choose surgery also differ systematically from people who choose medication.
The practical read: this is not an either-or. Tens of thousands of people in the US cohort were doing both [3].
What should I ask my care team about?
These are conversation starters, not instructions. Every decision here belongs to you and a healthcare provider who knows your surgical anatomy.
Nutrition and muscle. Post-bariatric patients already face micronutrient risk and altered absorption. Adding a drug that further reduces intake raises the stakes on protein, vitamins and follow-up labs.
Post-bariatric hypoglycemia. This is a recognized late complication of gastric bypass. A 2026 case report in JCEM Case Reports described three patients treated with tirzepatide for post-bariatric hypoglycemia after gastric bypass [9]. Three patients is a case report, not evidence of benefit, and this is an area where individualized specialist input matters.
Anatomy first. If there is a mechanical problem, such as a dilated pouch, a fistula or a stricture, medication does not fix it.
What happens if you stop. Weight regain after discontinuation is well documented in the general obesity population, and there is no reason post-bariatric patients would be exempt. Ask what the plan is if coverage lapses.
Which drug and which label. Be precise with your team: Wegovy and Ozempic are semaglutide; Zepbound and Mounjaro are tirzepatide. The Wegovy label sets its own BMI and comorbidity criteria for the obesity indication, and none of these products carries a post-bariatric indication [10].
The honest summary
The evidence has moved fast. Two years ago, adding a GLP-1 drug after bariatric surgery was supported by case series. Now there is a randomized trial showing 18 percent weight loss over 68 weeks, a 208,000-patient cohort showing tirzepatide outperforming semaglutide in routine care, and a meta-analysis pooling more conservative real-world figures [2][3][4].
What is still missing: a randomized comparison of tirzepatide against semaglutide in this population, a randomized comparison of medication against revision surgery, anything beyond 68 weeks, and any data at all on what happens to bone and lean mass in people who have already lost a great deal of both.
On what to do first, the Cureus review is the thing to read rather than this article: it sets out a stepwise approach that starts with assessing the surgical anatomy, then optimizing lifestyle, then considering pharmacotherapy, and reserves revision for genuine anatomical failure [1]. Its reasoning is that medication cannot correct a mechanical problem, so the anatomy question comes first. Whether that sequence applies to you is a question for the team that knows your operation.
Sources
- Huerta Díaz LA, et al. Weight Recurrence After Bariatric Surgery: Incretin-Based Therapies and the Evolving Role of Revisional Surgery. Cureus. 2026. https://doi.org/10.7759/cureus.113460
- Stanley C, Mallik R, Hamid N, et al. Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial (BARI-STEP). Nature Medicine. 2026 Jul;32(7):2662-2672 (epub 2026 May 22). NCT05073835. https://doi.org/10.1038/s41591-026-04416-4
- Gillikin A, Lee Y, Varney C, Dang JT, Tsung A, Nimeri A, Shin TH. Weight loss and cardiovascular outcomes with incretin-based therapies after metabolic and bariatric surgery: a nationwide US cohort study. EClinicalMedicine. 2026 Jun 23;97:104033. https://doi.org/10.1016/j.eclinm.2026.104033
- Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery: a systematic review and meta-analysis. Frontiers in Endocrinology. 2026 Aug 26. https://doi.org/10.3389/fendo.2026.1870008
- Tackling suboptimal clinical response after metabolic bariatric surgery: impact of tirzepatide on weight loss and body composition. Obesity Research and Clinical Practice. 2025. https://doi.org/10.1016/j.orcp.2025.02.004
- Sleeve-to-bypass conversion vs. sleeve-with-adjuvant GLP-1 receptor agonists: an academic multicenter retrospective study. Surgical Endoscopy. Published online 2025 Jul 21. https://doi.org/10.1007/s00464-025-11942-8
- GRABS trial design and baseline characteristics. Diabetes, Obesity and Metabolism. 2026. https://doi.org/10.1111/dom.71320
- Comparative Cardiovascular Outcomes of GLP-1 Receptor Agonists Versus Bariatric Surgery: A Systematic Review and Network Meta-Analysis. Endocrinology, Diabetes and Metabolism. 2026 Sep. https://doi.org/10.1002/edm2.70311
- Tirzepatide for treatment of postbariatric hypoglycemia after Roux-en-Y gastric bypass: a report of cases. JCEM Case Reports. 2026 Sep 3. https://doi.org/10.1210/jcemcr/luag216
- Wegovy (semaglutide) US prescribing information, revised 06/2026. Novo Nordisk. https://www.novo-pi.com/wegovy.pdf
Questions people ask
Can you take Ozempic or Wegovy after gastric sleeve surgery?
There is no label rule against it, and it is now common. No GLP-1 or dual incretin drug carries a separate indication for post-bariatric use, so prescribing happens under the existing obesity indication when the BMI criteria are met. The evidence base is a 2026 randomized trial plus several large observational cohorts.
How much weight do people lose on a GLP-1 drug after bariatric surgery?
It depends heavily on the study design. In BARI-STEP, the only randomized trial, people lost an average of 18.0 percent of body weight over 68 weeks on semaglutide 2.4 mg versus a 0.4 percent gain on placebo. That trial enrolled 70 people at two London hospitals, not in the US. In a 208,155-patient US cohort of routine care, one-year total weight loss was 17.2 percent with tirzepatide and 12.0 percent with semaglutide. A meta-analysis of mostly observational studies pooled lower figures, around 9 percent at 12 months for liraglutide and semaglutide.
Is tirzepatide better than semaglutide after bariatric surgery?
Every comparison so far points that way, but none of them is a randomized head-to-head trial. The US nationwide cohort found tirzepatide produced 5.16 percentage points more total weight loss than semaglutide at one year, and a 2026 meta-analysis found a 4.23 percentage point advantage at 6 months. Both are observational comparisons.
Should I get revision surgery or try a GLP-1 drug first?
That is a conversation for your surgical team, and the answer depends on whether there is an anatomical problem to fix. A 2026 review describes a stepwise approach: assess the anatomy first, optimize lifestyle, then try medication, and reserve revision for anatomical failure. The one large comparison of sleeve-to-bypass conversion against sleeve-plus-medication, in 4,901 patients, was retrospective.
Does it matter how long after surgery you start?
In the US nationwide cohort it did. People who started an incretin drug later after surgery, in postoperative months 53 to 79, had greater total weight loss (15.4 percent) than those who started in months 12 to 24 (13.5 percent). That is an observational pattern, not a scheduling rule, and it may just reflect who was still regaining weight at each point.
Are the side effects different after bariatric surgery?
The randomized trial reported adverse events consistent with the known semaglutide profile, with no new safety concerns specific to the post-bariatric population. A 2026 meta-analysis of post-surgical patients likewise reported no serious adverse events and mostly mild gastrointestinal symptoms. One group needs specific attention: people with post-bariatric hypoglycemia after gastric bypass, where published experience is limited to case reports.
Will insurance cover a GLP-1 drug after bariatric surgery?
Coverage runs through the obesity indication, not through a post-surgical one, so it depends on your current BMI and your plan's criteria. Some plans require documented weight regain; others exclude anti-obesity medication entirely. Coverage rules change often, so check your plan's current criteria.
Do GLP-1 drugs work as well as bariatric surgery?
For weight, modern drugs have closed much of the gap, but for hard cardiovascular outcomes a 2026 network meta-analysis of 43 studies and 932,380 patients still favors surgery: hazard ratio 0.66 for major adverse cardiovascular events with surgery versus 0.85 with GLP-1 drugs. No randomized trial has compared surgery head-to-head with a modern GLP-1 drug.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.